Oseltamivir-resistant pandemic (H1N1) 2009 influenza in a severely ill patient: The first Australian case

Medical Journal of Australia

Volumn 192, Issue 3, 2010, Pages 166-168

  Speers, David J ^a,b   Williams, Simon H ^a   Pinder, Mary ^b   Moody, Harry R ^b   Hurt, Aeron C ^c   Smith, David W ^a,d  

^a PATHWEST LABORATORY MEDICINE   (Australia)

^b SIR CHARLES GAIRDNER HOSPITAL   (Australia)

^c WHO COLLABORATING CENTRE FOR REFERENCE AND RESEARCH ON INFLUENZA   (Australia)

^d UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; OSELTAMIVIR; ZANAMIVIR;

ADULT; ANURIA; ARTICLE; AUSTRALIA; CADAVER; CASE REPORT; COMMUNITY ACQUIRED PNEUMONIA; DISEASE COURSE; DISEASE SEVERITY; DISEASE SURVEILLANCE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG MEGADOSE; FEVER; GRAFT RECIPIENT; HEMOFILTRATION; HUMAN; HYPOXIA; IC 50; IMMUNOSUPPRESSIVE TREATMENT; INFLUENZA; INFLUENZA VIRUS A H1N1; KIDNEY TRANSPLANTATION; LUNG LAVAGE; MYALGIA; PANDEMIC; REAL TIME POLYMERASE CHAIN REACTION; RECOMMENDED DRUG DOSE; RESPIRATORY FAILURE; TACHYPNEA; THORAX RADIOGRAPHY; TREATMENT DURATION; VIRUS PNEUMONIA;

EID: 77952408198     PISSN: 0025729X     EISSN: 13265377     Source Type: Journal    
DOI: 10.5694/j.1326-5377.2010.tb03459.x     Document Type: Article

References (9)

1. Robson R, Buttimore A, Lynn K, et al. The pharmacokinetics and tolerability of oseltamivir suspension in patients on haemodialysis and continuous ambulatory peritoneal dialysis. Nephrol Dial Transplant 2006; 21: 2556-2562. (Pubitemid 44644531)
2. Karie S, Launay-Vacher V, Janus N, et al. Pharmacokinetics and dosage adjustment of oseltamivir and zanamivir in patients with renal failure. Nephrol Dial Transplant 2006; 21: 3606-3608. (Pubitemid 44817131)
3. Taylor WRJ, Thinh BN, Anh GT, et al. Oseltamivir is adequately absorbed following nasogastric administration to adult patients with severe H5N1 influenza. PLoS One 2008; 3: e3410.
4. Hurt AC, Holien JK, Barr IG. In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses. Antimicrob Agents Chemother 2009; 53: 4433-4440.
5. Moscona A. Global transmission of oseltamivir-resistant influenza. N Engl J Med 2009; 360: 953-956.
6. Hurt AC, Ernest J, Deng YM, et al. Emergence and spread of oseltamivirresistant A(H1N1) influenza viruses in Oceania, South East Asia and South Africa. Antiviral Res 2009; 83: 90-93.
7. World Health Organization. Global Alert and Response. Pandemic (H1N1) 2009 - update 69. 9 Oct 2009. http://www.who.int/csr/don/2009-10-09/en/index. html (accessed Dec 2009).
8. Leung TW, Tai AL, Cheng PK, et al. Detection of an oseltamivir-resistant pandemic influenza A/H1N1 virus in Hong Kong. J Clin Virol 2009; 46: 298-299.
9. Centers for Disease Control and Prevention (CDC). Oseltamivir-resistant novel influenza A (H1N1) virus infection in two immunosuppressed patients - Seattle, Washington, 2009. MMWR Morb Mortal Wkly Rep 2009; 58: 893-896.